NeuroIndex
EEG for Preventing Brain Injury During Anesthesia
Company Overview
Snapshot
Founded in April 2017, NeuroIndex operates with 1–10 employees. The company secured funding in one round from one investor, Alon MedTech Ventures, in January 2020. NeuroIndex ceased operations in April 2022.
Business overview
NeuroIndex is developing an AI-based brain health platform designed to prevent brain damage during anesthesia. The core technology utilizes EEG signals in response to sound stimuli, processed by an AI system. The device, which includes a single-use headset for EEG monitoring and a processing unit, aims to identify and report real-time indications of brain damage during surgery. This enables anesthesiologists to intervene promptly, reducing the risk of post-operative neurocognitive disorders (PND). The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Monitors, serving the healthcare provider market.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroIndex's primary focus?
- NeuroIndex focuses on developing an AI-based brain health platform that uses EEG signals to prevent brain damage during anesthesia.
- When was NeuroIndex founded?
- NeuroIndex was founded in April 2017.
- What is the status of NeuroIndex?
- NeuroIndex is currently non-active and ceased operations in April 2022.
- What technology does NeuroIndex utilize?
- NeuroIndex utilizes AI and EEG signals to monitor brain health and detect potential damage during surgical procedures under anesthesia.